CorticorpNews
Back to Science & Tech
Expand

Wilfredor · CC BY-SA 4.0 · Wikimedia Commons

Updated

Researchers from the University of Gothenburg and the University of Copenhagen reviewed evidence on whether GLP-1 drugs such as semaglutide and tirzepatide, used for obesity and type 2 diabetes, may affect brain health, and published the review in the journal Science. Growing evidence suggests these weight loss drugs may affect brain health, and studies have linked GLP-1 medications to lower dementia risk. Major trials found that semaglutide did not slow Alzheimer's disease, but scientists suspect the drugs may help preserve memory in people with obesity or diabetes. The review said animal studies suggest GLP-1 medications can influence learning and memory, while human findings are less consistent. Health record analyses found an association with lower dementia risk among people with type 2 diabetes, but these observational findings cannot show that the drugs cause the lower risk. In Novo Nordisk's EVOKE and EVOKE+ trials, semaglutide changed several Alzheimer's-linked biological markers without measurably slowing early disease. The authors suggested that cognitive problems linked to metabolic health might respond differently to treatment, and called for trials that track memory and attention from the start of treatment, noting that rapid weight loss can reduce muscle mass, especially in older or frail people.

Sources:ScienceDaily

1 outlet · 1 article · first seen Nov 17, 7:37 AM ET

Every source article